Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

REGENXBIO agrees to acquire rare metabolic disease-focused Dimension Therapeutics; later outbid

Executive Summary

REGENXBIO Inc. agreed to acquire fellow public biotech Dimension Therapeutics Inc. in an all stock deal for an implied value of $3.41 per share (a slight premium). Each outstanding share of Dimension will be converted into the right to receive 0.1573 shares of REGENXBIO; Dimension shareholders are estimated to own 10.9% of the combined entity.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies